Literature DB >> 8627046

Treatment of Myocardium avium complex infection: does the beige mouse model predict therapeutic outcome in humans?

J P Sison1, Y Yao, C A Kemper, J R Hamilton, E Brummer, D A Stevens, S C Deresinski.   

Abstract

To determine the predictive value of a standard murine model in the treatment of disseminated Myocardium avium complex (MAC) infection, beige mice were infected with MAC strains isolated from human immunodeficiency virus-infected patients and treated with the same antibiotic (ethambutol, clofazimine, or rifampin) that had been administered to the subject from whom that strain had been recovered. While ethambutol had the greatest bacteriologic efficacy in humans (mean decrease +/-SD, 1.0+/-0.5 log 10 cfu/mL of blood), clofazimine had the greatest bacteriostatic efficacy in mice (mean decrease +/- SD, 2.8 +/- 0.7 log(10) cfu/g of tissue). A linear correlation was not observed between bacteriostatic activity in mouse liver or spleen and the degree of bacteriologic response in humans (P > or = to .1). Odds ratios for a response in humans based on a bacteriologic response in mice were not significant for each agent (P > or = to .1, all cases).

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8627046     DOI: 10.1093/infdis/173.3.750

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  2 in total

1.  Characterization of mouse models of Mycobacterium avium complex infection and evaluation of drug combinations.

Authors:  Claire Andréjak; Deepak V Almeida; Sandeep Tyagi; Paul J Converse; Nicole C Ammerman; Jacques H Grosset
Journal:  Antimicrob Agents Chemother       Date:  2015-01-26       Impact factor: 5.191

2.  Ethambutol optimal clinical dose and susceptibility breakpoint identification by use of a novel pharmacokinetic-pharmacodynamic model of disseminated intracellular Mycobacterium avium.

Authors:  Devyani Deshpande; Shashikant Srivastava; Claudia Meek; Richard Leff; Tawanda Gumbo
Journal:  Antimicrob Agents Chemother       Date:  2010-03-15       Impact factor: 5.191

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.